Cancer

On October 14, 2025, the National Agency for Regional Health Services (AGENAS) published the list of technologies prioritized for evaluation within the National HTA Program for Medical Devices in 2025. Technologies from the fields of endocrinology, men’s health, neurology/neurosurgery, and radiotherapy have been identified as priorities and are currently undergoing health technology assessment.

In September 2025, the National Institute for Health and Care Research (NIHR) in England released four Med Tech-related assessments in its HTA Journal, which concerned pulmonology, in-vitro diagnostics, cardiology, and dermatology fields.

In July 2025, the HTA body of Tuscany Regional Healthcare published nine rapid HTA reports (eight new assessments and one reassessment) of medical devices in the ENT, neurosurgery, ophthalmology, orthopedics, peripheral vascular, and surgical procedures fields.

In August 2025, the Common Catalog of Genetic and Genomic Tests of the National Health System in Spain was updated. Two sections with a total of 140 new genetic tests were introduced: one for bone diseases, including craniofacial anomalies, and another for kidney diseases and urogenital disorders. Furthermore, six new tests were added in pediatric oncohematology. Other changes concerned adult oncohaematology, hereditary metabolic, and mitochondrial diseases.

In July 2025, the Dutch Organization for Health Research and Development (ZonMw) awarded twelve projects under the 2026 round of the Efficiency Research program concerning e-health, diagnostic imaging, gastrointestinal, endoscopy, orthopedics, gynecology, pulmonology, and cardiology fields.

On July 15, 2025, the Ministry of Labor, Health, Solidarity, and Families published the instruction on the application for coverage with evidence development programs for 2025-2026. The instruction details the specific fields of research, the application procedures, and the deadlines for different types of programs (PHRC, PRME, PREPS, PHRIP, and PRT).

On July 9, 2025, the NHS Cancer Programme granted £14.4 million to seven projects through the third Innovation Open Call. The projects aimed to fast-track the implementation of proven, late-stage innovations for the early detection and diagnosis of cancer.

The new Swiss outpatient billing system, comprising the TARDOC catalog of individual service tariffs and outpatient flat rates, approved by the Federal Council, is expected to take effect on January 1, 2026. On July 15, 2025, the Organization for Outpatient Physician Tariffs (OAAT AG) requested pre-launch adjustments to this system concerning hospital emergency and non-physician services, combination therapy in cancer treatment, wound care, and pathology services.

In the first and second quarters of 2025, the Dutch Healthcare Institute (ZIN) published three coverage positions concerning the ENT, gastrointestinal, and in-vitro diagnostic fields. Two of the three decisions (Internal nasal valve correction for airway blockage and molecular diagnostics of the NTRK gene fusion in cancer patients) received favorable recommendations for coverage under basic health insurance.

On June 6, 2025, NHS England published an updated work plan for the development of Clinical Commissioning Policies for specialised services. Two new MedTech-related policies concerning interventional radiology were added to the work program, and none have been published since the previous update. The status of ongoing policies has also been updated.

In May 2025, Health Technology Wales (HTW) accomplished one full appraisal on advanced electrosurgical bipolar vessel sealing systems during hysterectomy. One Med Tech-related Topic Exploration Report was published on AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas.

In May 2025, the National Institute for Health and Care Excellence (NICE) published two new Early Value Assessments (Digital therapy for chronic tic disorders and Tourette syndrome, AI technologies for skin lesions) and one new Late Stage Assessment (Drug-eluting stents for coronary artery disease). Furthermore, three clinical guidelines were updated.